198 related articles for article (PubMed ID: 17262903)
1. [Metastatic colorectal cancer: adjournments from ESMO 2006].
Bonetti A; Cascinu S; Falcone A; Maiello E; Zaniboni A; Aschele C
Tumori; 2006; 92(6):1-12. PubMed ID: 17262903
[No Abstract] [Full Text] [Related]
2. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Landherr L; Nagykálnai T
Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
[TBL] [Abstract][Full Text] [Related]
3. Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
Maung K; Lee D; DeGrendele HC; Schilsky R; Chu E; Jain VK; Copur S
Clin Colorectal Cancer; 2002 Nov; 2(3):140-5. PubMed ID: 12482329
[No Abstract] [Full Text] [Related]
4. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Ducreux M; Köhne CH; Schwartz GK; Vanhoefer U
Ann Oncol; 2003; 14 Suppl 2():ii17-23. PubMed ID: 12810453
[TBL] [Abstract][Full Text] [Related]
6. Common side effects and interactions of colorectal cancer therapeutic agents.
Holt K
J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717
[No Abstract] [Full Text] [Related]
7. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
Chu E
Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
[No Abstract] [Full Text] [Related]
8. 25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000.
D'Orazio AI; Gambill BD
Clin Colorectal Cancer; 2001 May; 1(1):10-5. PubMed ID: 12445373
[No Abstract] [Full Text] [Related]
9. First-line therapeutic strategies in metastatic colorectal cancer.
Davies JM; Goldberg RM
Oncology (Williston Park); 2008 Nov; 22(13):1470-9. PubMed ID: 19133603
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Moosmann N; Heinemann V
Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
[TBL] [Abstract][Full Text] [Related]
11. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Dohn LH; Jensen BV; Larsen FO
Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
[No Abstract] [Full Text] [Related]
12. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Ku GY; Haaland BA; de Lima Lopes G
Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
[TBL] [Abstract][Full Text] [Related]
13. Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Silvestris N; Maiello E; De Vita F; Cinieri S; Santini D; Russo A; Tommasi S; Azzariti A; Numico G; Pisconti S; Petriella D; Lorusso V; Millaku A; Colucci G
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S46-55. PubMed ID: 21129610
[TBL] [Abstract][Full Text] [Related]
14. Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008.
Gibson TB; Grothey E; Chu E
Clin Colorectal Cancer; 2008 Jul; 7(4):233-9. PubMed ID: 18650191
[No Abstract] [Full Text] [Related]
15. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
16. New developments in systemic chemotherapy in advanced colorectal cancer.
Cats A
Scand J Gastroenterol Suppl; 2003; (239):78-86. PubMed ID: 14743888
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
Booth C
J Clin Oncol; 2008 Oct; 26(28):4693-4; author reply 4694-5. PubMed ID: 18824719
[No Abstract] [Full Text] [Related]
18. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Schmiegel W; Reinacher-Schick A; Arnold D; Kubicka S; Freier W; Dietrich G; Geißler M; Hegewisch-Becker S; Tannapfel A; Pohl M; Hinke A; Schmoll HJ; Graeven U
Ann Oncol; 2013 Jun; 24(6):1580-7. PubMed ID: 23463625
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
